

Abstract

Antiandrogenic gestagens in a daily dose unit which corresponds to a maximum of twice the ovulation-inhibiting dose are used in combination with (6S)-5-methyltetrahydrofolate for the preparation of pharmaceutical preparations for therapy of endometriosis with simultaneous reduction of therapy side effects, such as the negative influence on bone density/bone metabolism and the risk of osteoporosis, and, at the onset of a pregnancy, reduction of the risk of congenital abnormalities, such as neural canal defects, cleft lip, jaw and palate, and pregnancy complications, such as abruptio placentae and premature birth.

The invention is suitable for long-term use.